东宝生物(300239) - 2021 Q4 - 年度财报

Production Capacity and Expansion - The company expanded its production capacity to 13,500 tons/year for gelatin and 4,300 tons/year for collagen, but faces sales risks due to market conditions and inventory levels [9]. - The company plans to expand its production capacity with new projects, including a 3,500-ton gelatin construction project and a 2,000-ton collagen project [31]. - The company plans to expand its capsule production capacity from 30 billion to 60 billion capsules over the next three years, indicating strong growth potential [72]. - The company has committed to invest 114,814.05 million RMB in various projects, with a significant portion allocated to the gelatin expansion project [170]. Financial Performance - The company's operating revenue for 2021 was ¥612,165,671.91, representing a 36.39% increase compared to ¥448,827,791.89 in 2020 [31]. - The net profit attributable to shareholders for 2021 was ¥36,484,130.69, a significant increase of 97.74% from ¥18,450,301.36 in 2020 [31]. - The net profit after deducting non-recurring gains and losses was ¥26,920,029.36, up 127.03% from ¥11,857,395.88 in 2020 [31]. - The total assets at the end of 2021 reached ¥2,112,240,503.24, marking a 48.97% increase from ¥1,417,934,200.36 at the end of 2020 [31]. - The net cash flow from operating activities for 2021 was ¥51,501,086.21, a decrease of 18.42% from ¥63,129,603.25 in 2020 [31]. Product Development and Innovation - In 2021, the company launched new products including beef bone collagen peptides and collagen protein sodium hyaluronate vitamin C powder, with plans for further product releases in 2022 [12]. - The company is focusing on technological innovation and product development in the fields of gelatin and collagen to enhance its competitive edge [48]. - The company is actively developing new products and enhancing its market presence, including launching new products and utilizing celebrity endorsements [48]. - The company has successfully developed a new collagen protein product, "shredded meat" plant-based product, and has made significant progress in the development of ultra-low endotoxin gelatin preparation technology [115]. Market Strategy and Presence - The company aims to strengthen its market presence by establishing trade offices in cities like Hangzhou, Shanghai, and Qingdao to boost sales of raw collagen products [9]. - The company is implementing a "Collagen+" strategy to enhance brand visibility and market share, including the use of celebrity endorsements [13]. - The company is actively expanding its market presence by optimizing product structure and launching new products, while enhancing channel and brand development [58]. - The company plans to enhance its online and offline sales channels, leveraging e-commerce and live streaming platforms to boost brand visibility [181]. Research and Development - The company has invested significantly in R&D, ranking among the top in the industry for new technologies and processes related to collagen and its derivatives [81]. - The company has established multiple research and development platforms, including key laboratories and innovation centers in Inner Mongolia and Qingdao [81]. - The company is collaborating with research institutions to enhance its R&D capabilities, particularly in the field of collagen peptides and their applications [88]. - The company is committed to maintaining high standards in product safety and efficacy, as demonstrated by its research on the toxicological safety of collagen peptides [96]. Acquisitions and Partnerships - The acquisition of Yiqing Bio has been integrated into the company's consolidated financial statements, expanding its operational scale and product range [7]. - The company acquired 60% of Qingdao Yiqing Biotechnology Co., Ltd. on November 30, 2021, which specializes in the production and sales of medicinal capsules, enhancing its position in the biopharmaceutical supply chain [135]. - The company has established partnerships with several universities and research institutions to support the development of bio-organic fertilizers and other products [116]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a focus on complementary businesses [92]. Governance and Compliance - The company has established a sound governance structure that complies with the regulations set forth by the China Securities Regulatory Commission [197]. - The board of directors consists of 7 members, including 3 independent directors, and operates in compliance with legal and regulatory requirements [196]. - The company actively communicates with stakeholders, ensuring the protection of their legal rights and interests [197]. - There are no significant discrepancies between the company's governance practices and the relevant laws and regulations [197]. Sustainability and Social Responsibility - The company is focused on sustainable practices, promoting a circular economy and resource recycling systems in line with national policies [56]. - The organic fertilizer segment is gaining traction due to government policies promoting sustainable agriculture, with the company positioned to benefit from this trend [51]. - The company is entering the fertilizer market with a resource utilization project, leveraging unique product advantages to capture opportunities in the agricultural sector [188]. - The company is committed to fostering a corporate culture that aligns with its parent company, enhancing employee engagement and operational efficiency [190].